1. Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting

    July 1, 2019

  2. Amphivena Expands Executive Team

    March 5, 2019

  3. Amphivena Presents at ASH First-in-Human Phase 1 Clinical Data on AMV564

    December 3, 2018

  4. Amphivena Presents Preclinical Data at ASH that Points to a Potentially New Treatment for MDS Patients

    December 9, 2017

  5. Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia

    November 29, 2017

  6. Amphivena Announces New Key Leadership and Advisors – Tekla Invests in Series B Round

    September 11, 2017

  7. Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation

    August 10, 2016

  8. Amphivena Therapeutics Presents Positive Data on Novel Acute Myeloid Leukemia (AML) Immunotherapy at 2015 ASCO Annual Meeting

    June 1, 2015

  9. Amphivena Therapeutics to Present Data on Novel Cancer Immunotherapy at 2015 ASCO Annual Meeting

    May 26, 2015

  10. Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen

    April 7, 2015

error: Content is protected !!